PINK:EVTCY
Delisted
Evotec Ag Ads Stock News
$14.16
+0 (+0%)
At Close: May 12, 2022
Evotec: Attractive Spec 'Buy', But Merck KGaA Is Still Better
08:42pm, Sunday, 12'th Nov 2023
Evotec SE's appeal is based on its valuation and upside potential in the drug discovery and development sector. The company's financial performance is average, with negative margins and subpar busines
Evotec wins orthopoxvirus antibody contract from U.S. government
01:59am, Wednesday, 05'th Jul 2023
Evotec's Seattle-based subsidiary has won a $74 million contract with the U.S. Department of Defence to develop monoclonal antibody-based drugs targeting orthopoxviruses, the German biotech firm said
Evotec SE (EVO) CEO Werner Lanthaler on Q4 2021 Results - Earnings Call Transcript
03:45pm, Tuesday, 12'th Apr 2022
Evotec SE (EVO) CEO Werner Lanthaler on Q4 2021 Results - Earnings Call Transcript
Why Are Evotec Shares Trading Lower On Friday?
02:44pm, Friday, 04'th Feb 2022
Bayer AG BAYRY has discontinued the development of eliapixant and will hand back full rights to the drug to Evotec SE EVO. Get the Inside Access Traders Are Using to Profit More and Win Bigger.
Evotec SE (EVOTF) CEO Werner Lanthaler on Q3 2021 Results - Earnings Call Transcript
01:34pm, Thursday, 11'th Nov 2021
Evotec SE (EVOTF) CEO Werner Lanthaler on Q3 2021 Results - Earnings Call Transcript
Evotec SE To Announce Results for the First Nine Months 2021 On 11 November 2021
09:30am, Wednesday, 03'rd Nov 2021
HAMBURG, GERMANY / ACCESSWIRE / November 3, 2021 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809) will announce its financial results for the first nine months 2021 on Thurs
Evotec SE Targets $576 Million U.S. IPO
02:03pm, Thursday, 28'th Oct 2021
Evotec SE has filed to raise $576 million in a U.S. IPO.
Evotec: Data-Driven R&D Company Filing New IPO
03:27pm, Wednesday, 27'th Oct 2021
Evotec is a leading drug discovery and development partner for the pharmaceutical and biotechnology industry.
Germany Based Evotec Sets Terms For $576M US IPO
01:10pm, Wednesday, 27'th Oct 2021
German biotech Evotec SE (OTC: EVTCY) plans to raise $576 million by offering 22 million ADSs at $26.16. At the proposed price, Evotec would command a market value of $9.2 billion.
Biotech Company Pasithea Therapeutics Teams Up With Evotec to Aid Mental Health Drug Discovery
10:08am, Monday, 11'th Oct 2021
Photo by CDC on Unsplash Pasithea Therapeutics ( NASDAQ: KTTA), a Florida-based biotechnology company, has teamed with life sciences company Evotec SE (OTCMKTS: EVTCY) as its research partner to help
Pasithea, Evotec Ink Drug Development Pact
08:34am, Monday, 11'th Oct 2021
Pasithea Therapeutics Corp (NASDAQ: KTTA) has initiated a new chemical entity development program and named Evotec SE (OTC: EVOTF) its research partner. No deal terms were disclosed.
Pasithea Therapeutics Corp. and Evotec SE Enter into Drug Development Agreement
08:20am, Monday, 11'th Oct 2021
-- Company contracts leading global drug development company to advance initial drug candidate -- Miami Beach, FL / October 11, 2021 -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or th
Evotec SE files Registration Statement for Proposed Offering of American Depositary Shares
02:00am, Monday, 11'th Oct 2021
HAMBURG, GERMANY / ACCESSWIRE / October 11, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that it has filed a registration statement on Form F-1 wit
Evotec Expands Neuroscience Collaboration with Bristol Myers
09:36am, Friday, 08'th Oct 2021
Bristol Myers Squibb & Co (NYSE: BMY) has expanded its neuroscience collaboration with Evotec SE (OTC: EVTCY) to include a new cell type. Related: Bristol Myers Exercises Option In-License Evo
Bristol Myers Exercises Option In-License Evotec's Neurodegenerative Candidate
09:46am, Thursday, 02'nd Sep 2021
Evotec SE (OTC: EVTCY) says that Bristol Myers Squibb Co (NYSE: BMY) has exercised its option to enter into an exclusive global license for EVT8683. It is the first program from the companies' br
